Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 6—June 2016

Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection

Florent ValourComments to Author , Thomas Perpoint, Agathe Sénéchal, Xiao-Fei Kong, Jacinta Bustamante, Tristan Ferry, Christian Chidiac, Florence Ader, on behalf of the Lyon TB study group
Author affiliations: Hospices Civils de Lyon, International Center for Research in Infectiology, Université Claude Bernard Lyon 1, INSERM U1111, Lyon, France (F. Valour, T. Perpoint, A. Sénéchal, T. Ferry, C. Chidiac, F. Ader); Necker-Enfants Malades Hospital, INSERM, Paris Descartes University, Paris, France (J. Bustamante); St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller University, New York, New York, USA (X.-E. Kong, J. Bustamante)

Main Article


Summary of clinically relevant characteristics of 64 case-patients with IFN-γ autoantibody-related nontuberculous mycobacterial infection found in literature review*

Characteristics Value
Female sex 40 (62.5)
Median age, y (IQR) 48.0 (44.8–60.0)
Asian origin
59 (92.2)
Other autoimmune diseases
7/27 (25.9)
Etiologic agents
Mycobaterium avium 23 (40.4)
M. abscessus 18 (31.6)
M. fortuitum 7 (12.3)
M. tuberculosis
6 (10.5)
Other opportunistic infections 39/52 (75.0)
Herpesviridae reactivations 23/52 (44.2)
Salmonella spp.
13/52 (25.0)
Median duration of intensive-phase therapy, mo (IQR) 31.0 (22.8–60.0)
≥6 31/31 (100)
≥12 29/31 (93.5)
≥18 27/31 (87.1)
23/31 (74.2)
Long-term antimicrobial suppressive therapy
3/30 (10.0)
Immunomodulatory therapies 10/30 (33.3)
Rituximab 6/30 (20.0)
IFN-γ 5/30 (16.7)
Intravenous immunoglobulins 2/30 (6.7)
Plasmapheresis 2/30 (6.7)
1/30 (3.3)
Cure 21/62 (33.9)
Improvement 6/62 (9.7)
Relapse/persistence 29/62 (46.8)
6/62 (9.7)
*Values are no. (%) except as indicated. Only articles with sufficient detail were analyzed. A complete listing of articles reviewed from the literature is provided in the online Technical Appendix Table ( IQR, interquartile range; IFN-γ, interferon gamma.
†Denominators indicate number of case-patients for which category of data was available.

Main Article

Page created: May 17, 2016
Page updated: May 17, 2016
Page reviewed: May 17, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.